変形性腰椎症に対するノーボシスパテの有効性と安全性
腰椎変性疾患により後方インスツルメンテーションおよび経椎間孔椎体間固定を必要とする患者の骨固定に対するノボシスパテの有効性と安全性を評価するためのスポンサー主導の臨床研究
This clinical study aims to evaluate the efficacy and safety of NOVOSIS PUTTY for bone fusion in patients requiring posterior instrumentation and transforaminal lumbar interbody fusion (TLIF) due to degenerative lumbar disease.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
The Subject is a patient requiring posterior instrumentation and transforaminal lumbar interbody fusion (TLIF) due to degenerative lumbar disease.
This clinical study aims to compare and evaluate the efficacy and safety of three dose groups of NOVOSIS PUTTY for bone fusion compared to the autologous bone in patients requiring posterior instrumentation and TLIF in the single level between L2 and S1(L2-S1) due to degenerative lumbar disease.
- Control Group (n=12): Local autologous bone
- Experimental Group 1 (n=12): Dose 1 (BMP2_1mg)
- Experimental Group 2 (n=12): Dose 2 (BMP2_2mg)
- Experimental Group 3 (n=12): Dose 3 (BMP2_3mg)
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Seoul、韓国、03312
- The Catholic University of Korea, Eunpyeong St. Mary's Hospital
-
Seoul、韓国、06591
- The Catholic University of Korea, Seoul ST. Mary's Hospital
-
Seoul、韓国、05505
- Asan medical center
-
Seoul、韓国
- Severance hospital
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adult aged ≥ 22 to ≤ 80 years
- Subjects whose skeletal maturation are confirmed by showing the result of Risser stage 5 in Risser classification, the Plain Radiography
- Subjects diagnosed with disc degeneration in the single level (L2-S1) lumbar spine along with spondylolisthesis of Meyerding grade 1 (degree of translocation: 0- <25%) or 2 (degree of translocation: 25- <50%) based on the results of radiological examination (CT, MRI, X-ray).
- Subjects with an ODI (Oswestry Disability Index) score of ≥ 35/100 at screening
- Subjects who were treated with non surgical treatment/therapy for at least 3 months, but were judged to have failed treatment by the investigator
- Subjects who are willing to participate in the study, comply with treatment and procedures, and visit the hospital for all observational evaluations
- Subjects who voluntarily signed the informed consent form after hearing the explanation on objectives and methods of this study
Exclusion Criteria:
- Subjects who have a history of medical device application (spinal instrumentation, for example, anterior disc replacement, interspinous device) to the target site or interbody fusion
- Subjects who are considered that the symptoms occurring in the lumbar region are not occurred by disc degeneration
- Subjects with active malignancy
- Subjects with a documented history of drug abuse (e.g., psychotropic drugs including narcotic analgesics and drugs with high dependence such as alcohol) within the last 6 months
- Subjects with a history of endocrine or metabolic disorders known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehler Danlos disease, or osteogenesis imperfecta)
- Subjects with BMI ≥ 35
- Subjects with spondylolis thesis/retrolisthesis with ≥ Grade 3 in the target level
- Subjects with a local acute infection at the current surgical site or active systemic infection (e.g., viral infections such as AIDS, HIV or hepatitis)
- Subjects with a history of metabolic or endocrine diseases known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers Danlos disease, osteogenesis imperfecta, fibrous dysplasia, etc.)
- Subjects with osteoporosis with a mean lumbar spine T-score of ≤ 2.5 on the DEXA bone density test and with a history of osteoporotic fractures (wrist fractures, femur fractures, lumbar spine fractures, etc.)
- Subjects who need to administer drugs that inhibit bone metabolism within 2 weeks after surgery, or Subjects who need to receive post operative drugs that are expected to interfere with bone fusion, such as steroids
- Subjects who smoke ≥ 20 cigarettes a day
- Subjects with autoimmune disease
- Subjects who were exposed to rhBMP 2 in the past
- Subjects who require to get fusion of two or more vertebral levels
- Subjects who have a pseudoarthrosis after previous fusion
- Subjects who had a history of at least one non fusion spinal surgery on the level to be operated
- Subjects who are considered to have a disease that hinders the accurate evaluation (e.g., neuromuscular disease, serious psychiatric disease) at the discretion of the investigator
- Subjects who are pregnant at screening or who are planning to become pregnant during the study participation period
- Subjects who are currently lactating or who are planning to lactate during the study
- Subjects who participated in studies for other drugs, biologics, or medical devices within 6 months from the date of surgery
- Subjects who are in a difficult situation to comply with study related matters
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
介入なし:Control Group
Local autologous bone |
|
|
実験的:Experimental Group 1
Dose 1(BMP2_1mg) |
NOVOSIS PUTTY is a product composed of recombinant human bone morphogenetic protein-2(BMP2) and β-tricalcium phosphate/hydrogel complex. |
|
実験的:Experimental Group 2
Dose 2(BMP2_2mg) |
NOVOSIS PUTTY is a product composed of recombinant human bone morphogenetic protein-2(BMP2) and β-tricalcium phosphate/hydrogel complex. |
|
実験的:Experimental Group 3
Dose 3(BMP2_3mg) |
NOVOSIS PUTTY is a product composed of recombinant human bone morphogenetic protein-2(BMP2) and β-tricalcium phosphate/hydrogel complex. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall bone fusion rate
時間枠:12 months after surgery
|
Meet the definition of bone fusion based on CT and the definition of bone fusion based on X-ray simultaneously. |
12 months after surgery
|
|
Overall fusion success rate
時間枠:12 months after surgery
|
Meet all of the following conditions:
|
12 months after surgery
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall fusion success rate
時間枠:6 and 24 months after surgery
|
Meet all of the following conditions:
|
6 and 24 months after surgery
|
|
Bone fusion rate
時間枠:6, 12, and 24 months after surgery
|
Bone fusion rate based on CT, X-ray |
6, 12, and 24 months after surgery
|
|
Oswestry Disability Index(ODI)
時間枠:6 weeks, 3, 6, 12, and 24 months after surgery
|
Evaluate Oswestry Disability Index(ODI) score/ lowest 0(best) to highest 50(worst) |
6 weeks, 3, 6, 12, and 24 months after surgery
|
|
SF-12 scores (general condition test)
時間枠:6 weeks, 3, 6, 12, and 24 months after surgery
|
Evaluate SF-12 scores / lowest 0(worst) to highest 100(best) |
6 weeks, 3, 6, 12, and 24 months after surgery
|
|
Numerical Rating Scale (NRS)
時間枠:6 weeks, 3, 6, 12, and 24 months after surgery
|
Evaluate Numerical Rating Scale (NRS) scores / lowest 0(best) to highest 30(worst) |
6 weeks, 3, 6, 12, and 24 months after surgery
|
|
Neurological Symptoms
時間枠:6 weeks, 3, 6, 12, and 24 months after surgery
|
Evaluate Neurological Symptoms test/ check among the 3 questions(Worsened/ Constent/Improved) best is imporved, worst is worsened |
6 weeks, 3, 6, 12, and 24 months after surgery
|
|
Satisfaction rate
時間枠:6 weeks, 3, 6, 12, and 24 months after surgery
|
Evaluate Satisfaction rate score / lowest 0(worst) to highest 3(best) |
6 weeks, 3, 6, 12, and 24 months after surgery
|
協力者と研究者
捜査官
捜査官
- スタディチェア:Jumi Han、CGBio Inc.
出版物と役立つリンク
一般刊行物
- Mobbs RJ, Phan K, Malham G, Seex K, Rao PJ. Lumbar interbody fusion: techniques, indications and comparison of interbody fusion options including PLIF, TLIF, MI-TLIF, OLIF/ATP, LLIF and ALIF. J Spine Surg. 2015 Dec;1(1):2-18. doi: 10.3978/j.issn.2414-469X.2015.10.05.
- GJESSING MH. Osteoplastic anterior fusion of the lower lumbar spine in spondylolisthesis, localized spondylosis, and tuberculous spondylitis. Acta Orthop Scand. 1951;20(3):200-13. doi: 10.3109/17453675108991168. No abstract available.
- Smith JS, Fu KM, Polly DW Jr, Sansur CA, Berven SH, Broadstone PA, Choma TJ, Goytan MJ, Noordeen HH, Knapp DR Jr, Hart RA, Donaldson WF 3rd, Perra JH, Boachie-Adjei O, Shaffrey CI. Complication rates of three common spine procedures and rates of thromboembolism following spine surgery based on 108,419 procedures: a report from the Scoliosis Research Society Morbidity and Mortality Committee. Spine (Phila Pa 1976). 2010 Nov 15;35(24):2140-9. doi: 10.1097/BRS.0b013e3181cbc8e7.
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- B2201
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。